NASDAQ: ALVRAllovir Inc Stock
$2.22-0.05 (-2.2%)
Updated Sep 27, 2023
ALVR Price
$2.22
Fair Value Price
N/A
Market Cap
$252.79M
52 Week Low
$1.90
52 Week High
$10.29
P/E
-1.24x
P/B
1.1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$166.66M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.23
Operating Cash Flow
-$126M
Beta
1.68
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ALVR Overview
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALVR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALVR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALVR is good value based on its book value relative to its share price (1.1x), compared to the US Biotechnology industry average (5.12x)
P/B vs Industry Valuation
ALVR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALVR due diligence checks available for Premium users.
Be the first to know about important ALVR news, forecast changes, insider trades & much more!
ALVR News
Valuation
ALVR fair value
Fair Value of ALVR stock based on Discounted Cash Flow (DCF)
Price
$2.22
Fair Value
$3.95
Undervalued by
43.80%
ALVR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALVR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.24x
Industry
13.5x
Market
13.45x
ALVR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.1x
Industry
5.12x
ALVR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALVR's financial health
Profit margin
Revenue
$0.0
Net Income
-$45.3M
Profit Margin
0%
ALVR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$282.7M
Liabilities
$53.6M
Debt to equity
0.23
ALVR's short-term assets ($252.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALVR's short-term assets ($252.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALVR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$27.1M
Investing
$37.9M
Financing
$0.0
ALVR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALVR vs Biotech Stocks
Allovir Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.